Featured news

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION REQUIRES A PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE CONTRAVENES APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH

Nanologica AB (publ) (“Nanologica”) has today entered into an agreement and completed the acquisition of all shares in Ardena Södertälje AB (“Syntagon”) from Ardena Sweden (the “Seller”). The purchase price amounts to approximately SEK 8.6 million and will be paid in the form of newly issued shares in Nanologica. Syntagon is a Contract Development and Manufacturing Organization with just over 45 employees, which in 2025 had sales of approximately SEK 80 million. Nanologica believes that

Nanologica has received an order for a non-silica-based purification media from a customer in Asia. The order value amounts to approximately SEK 1.5 million. “To broaden our portfolio of chromatography media, we have a development program for additional applications. We are at an early stage and are therefore pleased to already receive a larger order. The visibility of revenue on this program is low, but in the long term it has the potential to provide

Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a new distribution partner in China. The order relates to sampling NLAB Saga® to pharmaceutical manufacturers.  “This order is a result of our production now being stable. Going forward we will have larger volumes of our silica products, which is why we are now increasing our sales efforts in China. We will continue to handle many customers ourselves, but also work

Nanologica has received a supplementary order for the company’s silica-based purification media NLAB Saga® from a customer in the US who placed an initial order of approximately SEK 1.3 million in June. The customer is a manufacturer of peptide drugs and the order relates to evaluation of NLAB Saga® on a production scale. In June, Nanologica received a first order from this customer in the US for evaluation of the company’s silica on a production